You are here: Industry Insights > Moderna

News List

Moderna announces dosing of first adolescent participants in Phase II-III trials of COVID-19 vaccine expresspharma
December 11, 2020
Moderna announced that the first adolescent participants have been dosed in the Phase 2/3 study of mRNA-1273, the company’s vaccine candidate against COVID-19, in adolescents ages 12 to less than 18.
NIAID study shows Moderna’s Covid-19 vaccine provides three-month immunity pharmaceutical-technology
December 07, 2020
Researchers at the National Institute for Allergies and Infectious Diseases (NIAID) have reported that Moderna’s Covid-19 vaccine, mRNA-1273, caused the human immune system to produce potent antibodies that endure for at least three months.
Moderna to supply six million doses of COVID-19 vaccine to Israel expresspharma
December 07, 2020
The company has already initiated the rolling regulatory review process with the Ministry of Health in Israel.
Moderna applies for regulatory authorisation for COVID-19 vaccine europeanpharmaceuticalreview
December 03, 2020
The company has submitted for Emergency Use Authorization in the US and Conditional Marketing Authorization in Europe for its mRNA-1273 vaccine against COVID-19.
EMA receives application for conditional marketing authorisation of Moderna COVID-19 vaccine worldpharmanews
December 02, 2020
EMA has received an application for conditional marketing authorisation (CMA) for a COVID-19 mRNA vaccine by Moderna Biotech Spain, S.L.
Recipharm Inks Covid-19 Vax Pact with Moderna contractpharma
December 02, 2020
Signs of letter of intent for aseptic fill-finish manufacturing of Moderna’s COVID-19 vaccine candidate (mRNA-1273).
UK secures total of 357 million doses of various COVID-19 vaccines europeanpharmaceuticalreview
December 01, 2020
After purchasing an additional two million doses of Moderna’s COVID-19 vaccine, the UK will now receive a total of 357 million doses of vaccines from seven developers.
UK to procure additional two million doses of mRNA vaccine against COVID-19 expresspharma
December 01, 2020
Moderna announced a supply agreement with the UK government for an additional two million doses of mRNA-1273, Moderna’s vaccine candidate against COVID-19, to the United Kingdom beginning in March 2021.
Moderna announces vaccine efficacy of 94.1 per cent, to file for EUA with US FDA expresspharma
December 01, 2020
Primary efficacy analysis of the Phase 3 COVE study of mRNA-1273 involving 30,000 participants included 196 cases of COVID-19, of which 30 cases were severe.
EU secures 80 million doses of Moderna COVID-19 vaccine europeanpharmaceuticalreview
November 30, 2020
The European Commission and Moderna have agreed that the company will supply at least 80 million doses of mRNA-1273, the company’s COVID-19 vaccine candidate.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 22 23 Next page